Biotech Values

[DewDiligence]

Note: MRK’s PR today presents the HCV data on a per-protocol basis rather than an ITT basis; i.e., MRK’s calculation of the SVR12 rates in various cohorts excludes patients who dropped out.

This is not to say that MRK’s data aren’t excellent—they are; however, PP data have an upward bias relative to ITT data, and this should be taken into account when comparing MRK’s results to those of other studies.